8-KOther EventsExhibits & Filings

BIOGEN INC. 8-K Report, Corporate Update (Apr 29, 2019)

Filed April 29, 2019For Securities:BIIB

Summary

Biogen Inc. (BIIB) filed an 8-K on April 29, 2019, to announce the nomination of three individuals – John R. Chiminski, William A. Hawkins, and Jesus B. Mantas – for election to its Board of Directors at the upcoming 2019 annual meeting of stockholders. This announcement, detailed in an attached press release, is a routine corporate governance update, signaling proposed changes or continuations to the company's leadership structure as determined by shareholder vote. Investors should note that this filing primarily concerns board nominations and the upcoming proxy solicitation process. Biogen emphasizes the importance of reviewing its forthcoming proxy statement, which will provide comprehensive details about the nominees, the meeting agenda, and potential proxy solicitations. The company also directs shareholders to existing SEC filings for information on director and executive officer stock ownership and interests.

Key Highlights

  • 1Biogen announced the nomination of John R. Chiminski, William A. Hawkins, and Jesus B. Mantas to its Board of Directors.
  • 2These nominations are for election at the Company's 2019 annual meeting of stockholders, scheduled for June 19, 2019.
  • 3The announcement was made via a press release filed as an exhibit to the 8-K.
  • 4The filing serves as notification of upcoming board composition changes subject to shareholder approval.
  • 5Biogen highlighted the forthcoming proxy statement, urging stockholders to review it for important information.
  • 6Information regarding director and executive officer stock ownership is available through prior SEC filings.

Frequently Asked Questions

The individuals nominated for election to Biogen's Board of Directors are John R. Chiminski, William A. Hawkins, and Jesus B. Mantas.

The election of these directors will take place at Biogen's 2019 annual meeting of stockholders, scheduled for June 19, 2019.

Biogen strongly encourages stockholders to read the upcoming proxy statement, which will be filed with the SEC and will contain important information about the nominees and the matters to be considered at the annual meeting. This document will be available on the SEC's website and Biogen's investor relations website.

No, this 8-K filing is specifically an 'Other Events' disclosure concerning the nomination of directors for the upcoming annual meeting and related proxy solicitations. It does not contain financial performance or operational updates.